03 September 2007

Schizophrenia breakthrough

The first new class of drugs in more than a decade for treating schizophrenia worked at least as well in a clinical trial as standard medications, a new study suggests.

The first new class of drugs in more than a decade for treating schizophrenia worked at least as well in a clinical trial as standard medications, a study released Sunday suggested.

Unlike current anti-psychotic drugs, which block the uptake of anaturally occurring chemical called dopamine, the new drug acts on a different neurotransmitter, glutamate.

The new treatment also reduced certain undesirable side-effects, according to the study, published in the British journal Nature Science.

Imbalances in the brain of these chemicals are largely responsible for schizophrenia's disabling symptoms, which range from hallucinations and delusions to a severely impaired ability to express emotion.

Environmental factors are thought to play a role too.

Sufferers often hear voices and may believe that other people are reading their minds or controlling their thoughts. These frightening experiences can cause withdrawal and extreme agitation.

No known cure
There is no known cure for the chronic disease, which affects approximately 1 in 250 people, emerging in men in their late teens and early 20s, and a decade later in women, according to the World Health Organisation.

Until now, the only drugs able to keep the most severe symptoms in check without debilitating side-effects acted on dopamine receptors.

Dopamine is the chemical messenger in the brain mainly involved with thinking, emotions, behaviour and perception.

In a double blind clinical trial, a team led by Sandeep Patil, a researcher at Eli Lilly, which funded the study, administered the new drug - known as LY2140023 - to 97 patients alongside smaller groups given placebos or olanzipine, a commonly prescribed anti-psychotic medication.

LY2140023 matched the effectiveness of olanzipine for both "positive" symptoms such as hallucinations as well as "negative" ones, including withdrawal.

Avoided adverse effects
As important, it avoided some of the adverse effects associated with dopamine-targeting drugs: weight gain, increases in blood fats called triglycerides, periodontitis and inflammation of the gums.

Scientists have suspected for decades that improper neurotransmission of glutamate was linked to schizophrenia, but up to now the precise mechanism was not understood.

The researchers cautioned that this was only a "proof-of-concept" study to see whether the drug held promise in the treatment of schizophrenia, and that more trials to test LY2140023 against other drugs and over long time periods were needed. – (Sapa-AFP)

Read more:
What is Schizophrenia?
Schizophrenia: A mother’s tale

September 2007


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Live healthier

Contraceptives and you »

Scientists create new contraceptive from seaweed Poor long-term birth control training leads to 'accidents'

7 birth control myths you should stop believing

Will the Pill make you gain weight? Can you fall pregnant while breastfeeding? We bust seven common myths about birth control.

Your digestive health »

Causes of digestive disorders 9 habits that could hurt your digestive system

Your tummy rumblings might help diagnose bowel disorder

With the assistance of an 'acoustic belt', doctors can now determine the cause of your tummy troubles.